Psychedelic drug MDMA faces questions as FDA considers approval for PTSD

FDA questions the safety and evidence behind using MDMA as a treatment for PTSD, despite showing rapid improvements in symptoms through therapy.

Concerns include interpreting the research, determining the source of improvement (MDMA or therapy), and addressing safety issues like heart risks and abuse potential.

Read at ABC7 San Francisco